Weston Kightlinger

Dr. Weston Kightlinger

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
WKWeston Kightlinger
Weston Kightlinger
KDKatherine E. Duncker
Katherine E. Duncker
ARAshvita Ramesh
Ashvita Ramesh
ATAriel H. Thames
Ariel H. Thames
ANAravind Natarajan
Aravind Natarajan
MJMichael C. Jewett
Michael C. Jewett
Glycosylation plays important roles in cellular function and endows protein therapeutics with beneficial properties. However, constructing biosynthetic pathways to study and engineer precise glycan structures on proteins remains a bottleneck. Here, we report a modular, versatile cell-free platform for glycosylation pathway assembly by rapid in vitro mixing and expression (GlycoPRIME). In GlycoPRIME, glycosylation pathways are assembled by mixing-and-matching cell-free synthesized glycosyltransferases that can elaborate a glucose primer installed onto protein targets by an N-glycosyltransferase. We demonstrate GlycoPRIME by constructing 37 putative protein glycosylation pathways, creating 23 unique glycan motifs, 18 of which have not yet been synthesized on proteins. We use selected pathways to synthesize a protein vaccine candidate with an α-galactose adjuvant motif in a one-pot cell-free system and human antibody constant regions with minimal sialic acid motifs in glycoengineered Escherichia coli. We anticipate that these methods and pathways will facilitate glycoscience and make possible new glycoengineering applications.

7 May 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
WKWeston Kightlinger
Weston Kightlinger
LLLiang Lin
Liang Lin
MRMadisen Rosztoczy
Madisen Rosztoczy
WLWenhao Li
Wenhao Li
Matthew Peter DeLisaMatthew Peter DeLisa
Matthew Peter DeLisa
MJMichael C. Jewett
Michael C. Jewett

11 June 2020 in ACS Synthetic Biology
Verified
Journal Article
Open access
WKWeston Kightlinger
Weston Kightlinger
KWKatherine F. Warfel
Katherine F. Warfel
Matthew Peter DeLisaMatthew Peter DeLisa
Matthew Peter DeLisa
MJMichael C. Jewett
Michael C. Jewett
Protein glycosylation, the attachment of sugars to amino acid side chains, can endow proteins with a wide variety of properties of great interest to the engineering biology community. However, natural glycosylation systems are limited in the diversity of glycoproteins they can synthesize, the scale at which they can be harnessed for biotechnology, and the homogeneity of glycoprotein structures they can produce. Here we provide an overview of the emerging field of synthetic glycobiology, the application of synthetic biology tools and design principles to better understand and engineer glycosylation. Specifically, we focus on how the biosynthetic and analytical tools of synthetic biology have been used to redesign glycosylation systems to obtain defined glycosylation structures on proteins for diverse applications in medicine, materials, and diagnostics. We review the key biological parts available to synthetic biologists interested in engineering glycoproteins to solve compelling problems in glycoscience, describe recent efforts to construct synthetic glycoprotein synthesis systems, and outline exemplary applications as well as new opportunities in this emerging space.

27 November 2017 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
JSJennifer A. Schoborg
Jennifer A. Schoborg
JHJasmine M. Hershewe
Jasmine M. Hershewe
JSJessica C. Stark
Jessica C. Stark
WKWeston Kightlinger
Weston Kightlinger
JKJames E. Kath
James E. Kath
MJMichael C. Jewett
Michael C. Jewett

1 January 2018 in Synthetic Biology
Verified
Journal Article
Open access
PDF file
XJXing Jin
Xing Jin
WKWeston Kightlinger
Weston Kightlinger
YKYong-Chan Kwon
Yong-Chan Kwon
Seok Hoon HongSeok Hoon Hong
Seok Hoon Hong
Colicins are antimicrobial proteins produced by Escherichia coli, which, upon secretion from the host, kill non-host E. coli strains by forming pores in the inner membrane and degrading internal cellular components such as DNA and RNA. Due to their unique cell-killing activities, colicins are considered viable alternatives to conventional antibiotics. Recombinant production of colicins requires co-production of immunity proteins to protect host cells; otherwise, the colicins are lethal to the host. In this study, we used cell-free protein synthesis (CFPS) to produce active colicins without the need for protein purification and co-production of immunity proteins. Cell-free synthesized colicins were active in killing model E. coli cells with different modes of cytotoxicity. Pore-forming colicins E1 and nuclease colicin E2 killed actively growing cells in a nutrient-rich medium, but the cytotoxicity of colicin Ia was low compared to E1 and E2. Moreover, colicin E1 effectively killed cells in a nutrient-free solution, while the activity of E2 was decreased compared to nutrient-rich conditions. Both colicins E1 and E2 decreased the level of persister cells (metabolically dormant cell populations that are insensitive to antibiotics) by up to six orders of magnitude compared to that of the rifampin pretreated persister cells. This study finds that colicins can eradicate non-growing cells including persisters, and that CFPS is a promising platform for rapid production and characterization of toxic proteins.

1 November 2020 in Journal of Industrial Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
JHJasmine Hershewe
Jasmine Hershewe
WKWeston Kightlinger
Weston Kightlinger
MJMichael C Jewett
Michael C Jewett
Protein glycosylation, the enzymatic modification of amino acid sidechains with sugar moieties, plays critical roles in cellular function, human health, and biotechnology. However, studying and producing defined glycoproteins remains challenging. Cell-free glycoprotein synthesis systems, in which protein synthesis and glycosylation are performed in crude cell extracts, offer new approaches to address these challenges. Here, we review versatile, state-of-the-art systems for biomanufacturing glycoproteins in prokaryotic and eukaryotic cell-free systems with natural and synthetic N-linked glycosylation pathways. We discuss existing challenges and future opportunities in the use of cell-free systems for the design, manufacture, and study of glycoprotein biomedicines.